SCHEMBL12834560

SCHEMBL12834560

CC1=C(C(=O)c2ccc(C(=O)O)cc2)C(=O)c2ccccc2C1=O

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 5/20 0.59
MEN1 O00255 4/20 0.59
L3MBTL1 Q9Y468 4/20 0.53
SMN1; SMN2 Q16637 4/20 0.53
HKDC1 Q2TB90 4/20 0.53
ALDH1A1 P00352 3/20 0.53
LMNA P02545 3/20 0.53
NPSR1 Q6W5P4 3/20 0.53
XBP1 P17861 1/20 0.53
SRD5A2 P31213 3/20 0.50
TTR P02766 2/20 0.50
PTPRC P08575 2/20 0.49
MAPT P10636 3/20 0.46
HTT P42858 3/20 0.46
APAF1 O14727 2/20 0.46
KDM4E B2RXH2 2/20 0.46
MITF O75030 1/20 0.46
TDP1 Q9NUW8 1/20 0.46
FGFR1 P11362 1/20 0.45
FGFR2 P21802 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12969793 0.95 MEN1 (0.55) KMT2AMEN1L3MBTL1SMN1; SMN2HKDC1
SCHEMBL7098579 0.91 ALDH1A1 (0.62) KMT2AMEN1L3MBTL1SMN1; SMN2HKDC1
SCHEMBL12761941 0.88 ALDH1A1 (0.51) KMT2AMEN1L3MBTL1SMN1; SMN2HKDC1
SCHEMBL12834559 0.87 LMNA (0.49) KMT2AMEN1L3MBTL1SMN1; SMN2HKDC1
SCHEMBL12834569 0.85 ALDH1A1 (0.47) KMT2AMEN1L3MBTL1SMN1; SMN2HKDC1
SCHEMBL12834565 0.85 KMT2A (0.51) KMT2AMEN1L3MBTL1SMN1; SMN2HKDC1
SCHEMBL12834576 0.85 ALDH1A1 (0.58) KMT2AMEN1L3MBTL1SMN1; SMN2HKDC1
SCHEMBL12834571 0.83 SRD5A2 (0.47) KMT2AMEN1L3MBTL1SMN1; SMN2HKDC1
SCHEMBL1507053 0.83 CDC25B (0.52) KMT2AMEN1L3MBTL1SMN1; SMN2HKDC1
SCHEMBL12834566 0.83 MAPT (0.53) KMT2AMEN1L3MBTL1SMN1; SMN2HKDC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2257515-B1 1,4-NAPHTHOQUINONE DERIVATIVES AND THERAPEUTIC USE THEREOF CENTRE NAT RECH SCIENT (FR) 2017-05-17 EP disclosed
US-9090549-B2 1,4-naphthoquinones derivatives and therapeutic use thereof CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S.) (FR) 2015-07-28 US disclosed
US-20110059972-A1 1,4-NAPHTHOQUINONES DERIVATIVES AND THERAPEUTIC USE THEREOF CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2011-03-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110059972-A1 1,4-NAPHTHOQUINONES DERIVATIVES AND THERAPEUTIC USE THEREOF NQO1, NDUFV2, RECQL KMT2A 2271/4885MEN1 2491/4885L3MBTL1 4372/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.